¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå ±Ô¸ð Á¶»ç : ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Inhaled Nitric Oxide Market Size study, by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others), and Regional Forecasts 2022-2032
»óǰÄÚµå : 1486450
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,084,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,945,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀº 2023³â ¾à 11¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇß°í, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 7.70% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò(iNO)´Â ƯÁ¤ È£Èí°ï¶õ ȯÀÚÀÇ »ê¼Ò °ø±ÞÀ» °³¼±ÇÏ´Â Ä¡·áÁ¦·Î »ç¿ëµÇ´Â ÀÇ·á¿ë °¡½ºÀÔ´Ï´Ù. ÀÏ»êÈ­Áú¼Ò´Â ÆóÀÇ Ç÷°üÀ» È®ÀåÇÏ¿© È¿°úÀûÀÎ »ê¼Ò ±³È¯¿¡ ÇʼöÀûÀÎ ºÎÀ§·ÎÀÇ Ç÷·ù¸¦ ÃËÁøÇÏ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. »êÈ­Áú¼Ò´Â ü³»¿¡¼­ ÀÚ¿¬ÀûÀ¸·Î »ý¼ºµÇ´Â ºÐÀÚ·Î Ç÷°ü È®Àå ¹× Ç÷¾Ð Á¶Àý¿¡ °ü¿©Çϸç, iNO´Â ÆóÀÇ »ê¼Ò°¡ dzºÎÇÑ ºÎÀ§¸¦ µÑ·¯½Î°í ÀÖ´Â Ç÷°üÀ» Ç¥ÀûÀ¸·Î »ï¾Æ Ç÷°üÀ» À̿ϽÃ۰í Ç÷·ù¸¦ Áõ°¡½ÃÄÑ ÀûÇ÷±¸°¡ ÃÖÀûÀÇ »ê¼Ò¸¦ Èí¼öÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ Ç¥Àû ÀÛ¿ëÀº ½Å»ý¾Æ È£Èí±â Ä¡·á, ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ±Þ¼ºÈ£Èí°ï¶õÁõÈıº µîÀÇ Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. µû¶ó¼­ iNO´Â ƯÈ÷ ½Å»ý¾Æ ¹× ÁßÁõ ȯÀÚÀÇ Ç÷°ü ¹× »ê¼ÒÈ­ ¹®Á¦¸¦ °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¼ºÀο¡¼­ iNO Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» µÞ¹ÞħÇϴ źźÇÑ ÀÓ»óÀû Áõ°Å´Â Àü ¼¼°è ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ Ãß¼¼ÀÔ´Ï´Ù.

ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀÇ ¼ºÀåÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü°ú ÇÔ²² ¿µÀ¯¾Æ¿Í ½Å»ý¾ÆÀÇ Æó ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Å©°Ô ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ½Å»ý¾ÆÀÇ ´Ù¾çÇÑ Æó Áúȯ Ä¡·á¿¡ ÀÖ¾î ÈíÀÔÇü ÀÏ»êÈ­Áú¼ÒÀÇ È¿°ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ 2024³âºÎÅÍ 2032³â±îÁö ÃßÁ¤ ±â°£ µ¿¾È ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ±¹¸³½ÉÆóÇ÷¾×¿¬±¸¼ÒÀÇ 2022³â ³í¹®Àº ÀϽÃÀû ºóÈ£Èí, ½Å»ý¾Æ È£Èí°ï¶õ ÁõÈıº(RDS), ½Å»ý¾Æ Áö¼Ó¼º Æó°íÇ÷¾Ð(PPHN), ¸ÞÄÚ´½ ÈíÀÎ ÁõÈıº, ±â°üÁöÆó ÀÌÇü¼ºÁõ(BPD) µî ½Å»ý¾Æ¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ È£Èí ¹®Á¦¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù. Áõ°¡¸¦ Ư¡À¸·Î ÇÏ´Â ½É°¢ÇÑ ÁúȯÀ¸·Î, ÀÏ»êÈ­Áú¼Ò ÈíÀÔ ¿ä¹ýÀÇ ÁÖ¿ä ÀûÀÀÁõÀÔ´Ï´Ù. ±× ±âÀü¿¡´Â ÆóÇ÷°üÀÇ ¼±ÅÃÀû È®Àå, »ê¼ÒÈ­ ÃËÁø, ħ½ÀÀû ÀΰøÈ£Èí±â ÀÇÁ¸µµ °¨¼Ò µîÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ Àú»ê¼Ò¼º È£ÈíºÎÀü Ä¡·á¿¡ ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò¸¦ ½ÂÀÎÇÑ °ÍÀº ±× äÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ½Å»ý¾Æ È£Èí±â ÇÕº´ÁõÀ» °ü¸®Çϱâ À§ÇØ ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò äÅÃÀÌ ±ÞÁõÇÏ¿© ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò¿¡ ÃÊÁ¡À» ¸ÂÃá ÁýÁßÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿Àº ÀÌ Ä¡·á¿ë °¡½º ½ÃÀå¿¡ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò´Â ´Ù¾çÇÑ Æó ¹× ½ÉÇ÷°ü°è Áúȯ¿¡ ´ëÇÑ À¯¸ÁÇÑ Ä¡·áÁ¦·Î¼­ Å« °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÇÇÐ ¹× ±â¼ú ¹ßÀüÀº ÈíÀÔÇü ÀÏ»êÈ­Áú¼ÒÀÇ Çõ½ÅÀûÀÎ ÀÀ¿ë ¹× Á¦Çü¿¡ ´ëÇÑ ¿¬±¸¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÌ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â Àü´Þ ¸ÞÄ¿´ÏÁò°ú Åõ¿© ÇÁ·ÎÅäÄÝÀ» °³¼±Çϰí ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò Ä¡·áÀÇ ÀûÀÀÁõÀ» È®´ëÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ´Ù¾çÇÑ Áö¿ªÀÇ ¾ö°ÝÇÑ Àû¿ë ±âÁذú ³ôÀº Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ 2022³âºÎÅÍ 2032³â±îÁö ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÌ ÀÖÀ¸¸ç, 2023³â ºÏ¹Ì´Â ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ Áö¿ªÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °í±Þ ÀÇ·á ½Ã¼³ÀÇ Á¸Àç¿Í ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ½ÇÁúÀûÀÎ ÀÇ·áºñ ¼öÁذú °°Àº ÁÖ¿ä ¿äÀÎÀÌ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì´Â ±¤¹üÀ§ÇÑ R&D ÀÌ´Ï¼ÅÆ¼ºêÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖÀ¸¸ç, À¯¸®ÇÑ ±ÔÁ¦ ȯ°æ°ú ÇÔ²² ÀÌ Áö¿ª¿¡¼­ ÈíÀÔÇü ÀÏ»êÈ­Áú¼Ò Á¦Ç°ÀÇ ¹ßÀü°ú »ó¾÷Àû ÀÌ¿ë °¡´É¼ºÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó°íÇ÷¾Ð, ½Å»ý¾Æ Àú»ê¼Ò¼º È£ÈíºÎÀü µî È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡ Æ÷ÇÔµÈ ÁÖ¿ä ½ÃÀå ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.
  • Air Liquide Healthcare(ÇÁ¶û½º)
  • SOL Group(ÀÌÅ»¸®¾Æ)
  • Matheson Tri-Gas Inc.
  • Merck KGaA(µ¶ÀÏ)
  • Mallinckrodt Pharmaceuticals(¿µ±¹)
  • Nu-Med Plus Inc.
  • Perma Pure LLC(¹Ì±¹)
  • Praxair Distribution Inc.
  • HALMA PLC(¿µ±¹)
  • LINDE PLC(µ¶ÀÏ)

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

Á¦6Àå ¼¼°èÀÇ ÈíÀÔ½Ä ÀÏ»êÈ­Áú¼Ò ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

Á¦7Àå °æÀï Á¤º¸

Á¦8Àå Á¶»ç °úÁ¤

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Inhaled Nitric Oxide Market is valued approximately at USD 1.12 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.70% over the forecast period 2024-2032. Inhaled nitric oxide (iNO) is a medical gas used as a therapeutic agent to improve oxygenation in individuals facing certain respiratory difficulties. It works by expanding blood vessels in the lungs, promoting better blood flow to areas essential for effective oxygen exchange. Nitric oxide is a naturally produced molecule in the body, playing a role in vasodilation and regulating blood pressure. . iNO targets blood vessels surrounding oxygen-rich areas in the lungs, promoting relaxation and heightened blood flow to facilitate optimal oxygen uptake by red blood cells. This targeted action is essential in treating conditions such as neonatal respiratory treatment, chronic obstructive pulmonary disease, acute respiratory distress syndrome, others. Accordingly, iNO plays a vital role in managing vascular and oxygenation issues, especially in neonatal and critical care scenarios. The robust clinical evidence supporting the efficacy and safety of iNO therapy in adults is a key trend supporting the growth of the Global Inhaled Nitric Oxide Market.

The growth of the inhaled nitric oxide market is anticipated to surge significantly due to increased adoption for managing pulmonary disorders in infants and newborns, coupled with a rise in respiratory disorders prevalence and advancements in healthcare infrastructure. Also, there is growing awareness regarding inhaled nitric oxide's effectiveness in treating various pulmonary conditions, especially in neonates, which is supporting the market expansion during the estimated period of 2024-2032. For instance, a 2022 article from the National Heart, Lung, and Blood Institute highlights the range of breathing problems affecting newborns, including transient tachypnea, neonatal respiratory distress syndrome (RDS), persistent pulmonary hypertension of the newborn (PPHN), meconium aspiration syndrome, and bronchopulmonary dysplasia (BPD). PPHN is a critical condition marked by heightened pulmonary vascular resistance is a primary indication for inhaled nitric oxide therapy. Its mechanism involves selective dilation of pulmonary blood vessels, enhancing oxygenation, and reducing reliance on invasive ventilation methods. Furthermore, the U.S. Food and Drug Administration's approval for inhaled nitric oxide in treating hypoxic respiratory failure further bolsters its adoption. Consequently, the surge in adoption of inhaled nitric oxide in order to manage respiratory complications in newborns is poised to drive the projected growth of the inhaled nitric oxide market. Furthermore, intensive research and development activities focused on inhaled nitric oxide are anticipated to present substantial growth opportunities within the market for this therapeutic gas. Inhaled nitric oxide has attracted considerable interest due to its promising therapeutic potential across a spectrum of pulmonary and cardiovascular conditions. The ongoing progress in medical science and technology has spurred investigations into innovative applications and formulations of inhaled nitric oxide, prompting heightened investments in research and development by pharmaceutical firms and research establishments. These initiatives aim to refine delivery mechanisms, dosage protocols, and broaden the scope of indications for inhaled nitric oxide therapy. However, stringent application norms across various regions, along with high costs incurred with the procedure is expected to hinder the market growth between 2022 and 2032.

The key regions considered for the global Inhaled Nitric Oxide Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America is a dominating region in the inhaled nitric oxide market and is projected to sustain its leading position with the highest number of market shares throughout the forecast period. Key factors such as presence of advanced healthcare facilities and substantial healthcare expenditure levels that facilitate the adoption of innovative treatments like inhaled nitric oxide are primarily bolstering the regional market growth. Moreover, North America benefits from extensive research and development initiatives, coupled with a favorable regulatory landscape, which have fostered the advancement and commercial availability of inhaled nitric oxide products in the region. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period owing to the rising prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and neonatal hypoxic respiratory failure.

Major market player included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Application

By Region:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1.Global Inhaled Nitric Oxide Market Definition and Research Assumptions

Chapter 2.Executive Summary

Chapter 3.Global Inhaled Nitric Oxide Market Dynamics

Chapter 4.Global Inhaled Nitric Oxide Market: Industry Analysis

Chapter 5.Global Inhaled Nitric Oxide Market Size & Forecasts by Application 2022-2032

Chapter 6.Global Inhaled Nitric Oxide Market Size & Forecasts by Region 2022-2032

Chapter 7.Competitive Intelligence

Chapter 8.Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â